Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus PT from Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has received a consensus rating of "Buy" from the six analysts that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.20.

Several research analysts have commented on GANX shares. Roth Mkm restated a "buy" rating and issued a $7.00 target price on shares of Gain Therapeutics in a research note on Tuesday, December 24th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday, March 17th. Scotiabank started coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price target for the company. Finally, Chardan Capital reiterated a "buy" rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday, March 28th.

Gain Therapeutics Stock Performance

GANX traded down $0.14 on Tuesday, hitting $1.65. The company's stock had a trading volume of 454,753 shares, compared to its average volume of 285,500. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $3.65. The firm has a market cap of $45.85 million, a P/E ratio of -1.50 and a beta of 0.18. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company's 50 day simple moving average is $2.18 and its 200-day simple moving average is $2.07.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.07. Analysts forecast that Gain Therapeutics will post -1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC purchased a new stake in Gain Therapeutics during the fourth quarter valued at about $65,000. Northern Trust Corp raised its holdings in shares of Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after buying an additional 39,642 shares in the last quarter. Marshall Wace LLP bought a new stake in Gain Therapeutics in the 4th quarter worth approximately $198,000. Jones Financial Companies Lllp boosted its stake in Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock worth $212,000 after buying an additional 44,750 shares in the last quarter. Finally, Sprott Inc. bought a new position in Gain Therapeutics during the fourth quarter valued at approximately $30,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.